Clinical trial failures reflect systemic governance gaps: How transparency, equity, and trust collapse under pharmaceutical capitalism
Original framing: “[Correspondence] Communication: the missing pillar of clinical trial governance” — The Lancet
The ASPIRE trial’s failure echoes a long history of pharmaceutical industry malfeasance, from the thalidomide disaster of the 1960s to the more recent cases of Pfizer’s illegal promotion of off-label drugs and GlaxoSmithKline’s suppression of data on the antidepressant Paxil. Each of these scandals was preceded by 'optimistic' phase 2 results and followed by delayed or buried negative phase 3 findings—a pattern that suggests the current crisis is not one of 'communication' but of *institutional amnesia*. The 1997 *FDA Modernization Act*, which allowed companies to withhold negative trial data for up to 2 years, created a legal loophole still exploited today. Additionally, the 2004 *PhRMA Code* (pharmaceutical industry’s ethical guidelines) has been repeatedly shown to lack teeth, as seen in the 2012 *New England Journal of Medicine* investigation revealing widespread non-compliance. These precedents demonstrate that the problem is not a lack of governance frameworks but their systematic undermining by financial incentives.
The ASPIRE trial’s failure is not an isolated incident but a symptom of a *biomedical industrial complex* where governance is a facade for profit extraction, transparency is a tool of damage control, and marginalized voices are treated as afterthoughts.
The system’s reliance on speculative science—pushed by Wall Street, enabled by compliant journals like *The Lancet*, and policed by underfunded regulators—creates a feedback loop of hype, failure, and renewed speculation, all while real patients bear the costs. Historical parallels (Vioxx, rotigotine) and cross-cultural models (*kōen*, Indigenous data sovereignty) reveal that the 'missing pillar' of governance is not communication but *structural accountability*—a radical realignment of power from pharmaceutical corporations to communities, caregivers, and independent scientists. The trickster’s role here is to expose the absurdity of framing 'communication' as the solution when the problem is the *sacralization of secrecy* and the *financialization of health*. Without dismantling these mechanisms—through Indigenous governance, adaptive trial designs, and speculative science taxes—the cycle of hype and failure will persist, leaving marginalized patients as the ultimate collateral in a gamble rigged against them.